Rani Therapeutics Holdings, Inc.
RANI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001856725
In the last 90 days, Rani Therapeutics Holdings, Inc. insiders filed 2 open-market purchases and 2 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Rani Therapeutics Holdings, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 74 | 1 | 68 | −5 |
| Shares | 42.7M | 3.67M | 45.7M | +6.59M (+16.9%) |
| Value | $31.4M | $2.69M | $34.7M | +$6.00M (+20.9%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Polar Asset Management Partners Inc. | 2,318,542 | $1.76M | 0.03% |
| Heights Capital Management, Inc | 934,580 | $710.7K | 0.16% |
| Citadel Advisors LLC | 641,995 | $488.2K | 0.00% |
| Marshall Wace, LLP | 586,265 | $445.6K | 0.00% |
| Renaissance Technologies LLC | 430,737 | $327.5K | 0.00% |
| J. Safra Sarasin Holding AG | 17,000 | $12.9K | 0.00% |
| XTX Topco Ltd | 16,959 | $12.9K | 0.00% |
| Rockefeller Capital Management L.P. | 11,545 | $8.78K | 0.00% |
| Advisor Group Holdings, Inc. | 3,787 | $2.88K | 0.00% |
| Group One Trading, L.P. | 3,724 | $2.83K | 0.00% |
| Northwestern Mutual Wealth Management Co | 1,100 | $836 | 0.00% |
Sold out (16)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| 683 Capital Management, LLC | 487,168 | $358.0K |
| Millennium Management LLC | 405,669 | $298.1K |
| Hudson Bay Capital Management LP | 153,331 | $112.7K |
| Omers Administration Corp | 76,500 | $56.2K |
| Qube Research & Technologies Ltd | 47,508 | $34.9K |
| Nine Masts Capital Ltd | 44,849 | $33.0K |
| Diametric Capital, LP | 33,208 | $24.4K |
| Unique Wealth Strategies, LLC | 24,600 | $18.1K |
| CTC Alternative Strategies, Ltd. | 23,622 | $17.4K |
| Brevan Howard Capital Management LP | 23,336 | $17.1K |
| Jefferies Financial Group Inc. | 22,221 | $16.3K |
| Bronte Capital Management Pty Ltd. | 14,868 | $10.9K |
| Catalyst Funds Management Pty Ltd | 14,800 | $10.9K |
| Schonfeld Strategic Advisors LLC | 14,200 | $10.4K |
| GF Fund Management Co. Ltd. | 2,175 | $1.60K |
| Federated Hermes, Inc. | 799 | $587 |
Not filed for Q2 2026 yet (1)
Institutions that held Rani Therapeutics Holdings, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| SymBiosis Capital Partners, LLC | 3,667,585 | $2.69M |